Phaseline

Targets › CD7

CD7 (T-cell antigen CD7): drug programs, companies and trials

18 programs from 13 companies in 22 trials: 19 Phase 1, 3 Phase 2; Oncology, Immunology; next expected readout Dec 2026.

Transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. Plays a costimulatory role in T-cell activation upon binding to its ligand K12/SECTM1. (UniProt, P09564)

Open in Phaseline: the race on CD7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Allotera TherapeuticsWU-CART-007
Anti-CD7 allogeneic CAR-T cell therapy
CD7Phase 2T-cell Acute Lymphoblastic LeukemiaDec 2026
PersonGen BioTherapeutics (Suzhou)PA3-17 injection
anti-CD7 CAR-T cell therapy
CD7Phase 2CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/LymphomaOct 2027
Institute of Hematology & Blood Diseases Hospital, ChinaCD7-CART
anti-CD7 CAR-T cell therapy
CD7Phase 2CD7 PositiveJan 2029
Essen BiotechCD5/CD7 CAR-T
Chimeric antigen receptor T cells targeting CD5 and CD7
CD5, CD7Phase 1T Cell LymphomaDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRD13-02
anti-CD7 CAR-T cell therapy
CD7Phase 1NK T-Cell LymphomaDec 2026
Beijing GoBroad Hospitalumbilical cord blood CD19-BCMA CAR-T cells
dual-targeted CAR-T cell therapy targeting CD19 and BCMA
CD19, BCMA, CD5, CD7Phase 1Refractory Lupus Nephritis; T-Cell Non-Hodgkin LymphomaApr 2027
Zhejiang UniversityMT027 CAR-T cells
CAR-T cells targeting CD7 antigen on malignant hematopoietic cells
CD7Phase 1Hematologic Diseases; B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid TumorsApr 2027
The General Hospital of Western Theater CommandCD7 CAR-T cell
CD7-targeted CAR-T cell therapy
CD7Phase 1Acute-LeukemiaDec 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD7-specific CAR-T Cells
anti-CD7 CAR-T cell therapy
CD7Phase 1Hematologic MalignancyDec 2027
Peking University People's HospitalCD7-targeted CAR-T cells
anti-CD7 CAR-T cell therapy
CD7Phase 1CD7+ T-ALL/LBLDec 2027
Beijing GoBroad HospitalAutologous CD7 CAR T-cell
CD7-targeted chimeric antigen receptor T-cell therapy
CD7Phase 1T-cell Acute Lymphoblastic LeukemiaMar 2028
Beijing GoBroad HospitalPrior-HSCT donor-derived CD7 CAR T-cell
CD7-targeted chimeric antigen receptor T-cell therapy
CD7Phase 1T-cell Acute Lymphoblastic LeukemiaMar 2028
Institute of Hematology & Blood Diseases Hospital, ChinasupCD7 CART cells
anti-CD7 CAR-T cell therapy
CD7Phase 1T Lymphoblastic Leukemia/LymphomaJun 2028
Institute of Hematology & Blood Diseases Hospital, ChinauCD7 CART
CAR-T cell therapy targeting CD7-positive cells
CD7Phase 1Acute Myeloid Leukemia (AML)Jun 2028
Bambino Gesù Hospital and Research InstituteCD7-CART01
anti-CD7 CAR-T cell therapy
CD7Phase 1T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaSep 2028
Baylor College of MedicineCD7.CAR/28zeta T Cells
CD7-targeted chimeric antigen receptor T cell therapy
CD7Phase 1T-cell Acute Lymphoblastic LymphomaDec 2028
Stephan Grupp MD PhDBEAM-201
anti-CD7 CAR-T cell therapy
CD7Phase 1T-Cell Acute Lymphoblastic Leukemia/LymphomaMay 2029
Hebei Senlang BiotechnologySENL101
CD7-targeting CAR-T cell therapy
CD7Phase 1T-lymphoblastic LymphomaAug 2038

Conditions

T-cell Acute Lymphoblastic Leukemia (3) Refractory Lupus Nephritis (2) T-Cell Non-Hodgkin Lymphoma (2) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (1) CD7+ T-ALL/LBL (1) T Cell Lymphoma (1) T-cell Acute Lymphoblastic Lymphoma (1) Hematologic Malignancy (1) Hematologic Diseases (1) B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors (1) CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma (1) NK T-Cell Lymphoma (1)

Modalities

other (17), protein or peptide (1)

Companies

Beijing GoBroad Hospital (3) Institute of Hematology & Blood Diseases Hospital, China (3) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) Stephan Grupp MD PhD (1) Peking University People's Hospital (1) Essen Biotech (1) Baylor College of Medicine (1) Zhejiang University (1) PersonGen BioTherapeutics (Suzhou) (1) Bambino Gesù Hospital and Research Institute (1) Allotera Therapeutics (1) The General Hospital of Western Theater Command (1) Hebei Senlang Biotechnology (1)

Related targets

CD5 (2) CD19 (1) BCMA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.